Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01407419 · ClinicalTrials.gov registry record · NA
The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population
A NA study, sponsored by CorEvitas.
- Completed
- Registry status
- NA
- Development phase
- 538
- Enrollment target
NCT01407419: Completed NA study, sponsored by CorEvitas.
NCT01407419 is a NA study that has completed, run by CorEvitas. The registered enrollment target is 538 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01407419, a NA study, has completed, sponsored by CorEvitas.
- COMPLETED
- Registry status
- NA
- Development phase
- 538 participants
- Enrollment target
Study Summary
The Treat to Target Trial is a clinical trial available to new and existing CORRONA (Data Collection Program) sites. Subjects are recruited to participate in this 12 month trial examining outcomes and feasibility of implementing a Treat to Target approach, when compared with a control group of subjects treated with usual care.
Primary Outcome
CDAI Score, rates of acceleration, frequency of visits, time to next visit conditional on disease activity, and probability of acceleration conditional on disease activity.
Interventions
- OTHER Treatment Acceleration
- OTHER Monthly Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-07 |
| Phase | NA |
What the finished NCT01407419 record still lists
NCT01407419 is an interventional study that assigns participants to a tested intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Treatment Acceleration is the first listed.
NCT01407419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01407419 about?
NCT01407419 is a clinical study titled "The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population". The Treat to Target Trial is a clinical trial available to new and existing CORRONA (Data Collection Program) sites. Subjects are recruited to participate in this 12 month trial examining outcomes and feasibility of implementing a Treat to Target approach, when compared with a control group of subje...
What is the current status of trial NCT01407419?
This trial is currently completed. It is a NA study. The enrollment target is 538 participants. The study started on 2011-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01407419?
The interventions under investigation include: Treatment Acceleration (OTHER), Monthly Assessment (OTHER).
Who is sponsoring clinical trial NCT01407419?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01407419's enrollment target sits among peer trials
538 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia